Abstract
Metabolic Dysfunction-Associated Steatohepatitis (MASH) represents a growing public health challenge, with an alarming global prevalence and progression to severe stages such as cirrhosis and hepatocellular carcinoma. Sexual dimorphism in MASH influences susceptibility, progression, and treatment response, requiring in-depth investigation. Recent evidence from our research group indicates…